| Patent Number |
Title Of Patent |
Date Issued |
| 6273598 |
Computer system and methods for producing morphogen analogs of human OP-1 |
August 14, 2001 |
| The invention disclosed herein provides methods and compositions for the computer-assisted design of morphogen analogs. Practice of the invention is enabled by the use of at least a portion of the atomic co-ordinates defining the three-dimensional structure of human osteogenic protein-1 |
| 6194376 |
Method for modulating inflammatory response comprising administering morphogen |
February 27, 2001 |
| The invention provides methods for alleviating immune cell mediated inflammatory responses to injury to mammalian tissue. The present methods make use of osteogenic protein 1(OP-1), which is appreciated herein as tissue morphogen, i.e., a substance competent to induce tissue-specific |
| 6110460 |
Methods of using morphogen analogs |
August 29, 2000 |
| Disclosed herein are methods and compositions for identifying morphogen analogs. Preferred methods rest on the use of test cells comprising DNA defining a morphogen-responsive transcription activating element operatively associated with a reporter gene. In certain embodiments, the me |
| 6103491 |
Methods and compositions for identifying morphogen analogs |
August 15, 2000 |
| Disclosed herein are methods and compositions for identifying morphogen analogs. The preferred methods and compositions relate to the discovery that morphogen upregulation of the mouse type X collagen promoter activity is mediated by a MEF-2 like sequence and required an adjacent AP-1 |
| 6093547 |
Morphogen cell surface receptor and screening for morphogen analogs |
July 25, 2000 |
| Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features and various other data characterizing a morphogen cell surface receptor; (2) methods for producing receptor proteins, including fragments thereof, using recombinant DNA technology; (3) methods |
| 6090776 |
Morphogen treatment of organ implants |
July 18, 2000 |
| The present invention is directed to methods and compositions for enhancing viability of organs and living tissues to be transplanted in a mammal. The methods and compositions provide a therapeutically effective concentration of a morphogen or morphogen-stimulating agent to the tissue or |
| 6090544 |
Methods and compositions for identifying morphogen analogs |
July 18, 2000 |
| Disclosed herein are methods and compositions for identifying morphogen analogs. The preferred methods and compositions relate to the discovery that morphogen upregulation of the mouse type X collagen promoter activity is mediated by a MEF-2 like sequence and requires an adjacent AP-1 |
| 6077823 |
Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
June 20, 2000 |
| The present invention is directed to methods and compositions for alleviating tissue destructive effects associated with the inflammatory response to tissue injury in a mammal. The methods and compositions include administering a therapeutically effective concentration of a morphogen |
| 6071695 |
Methods and products for identification of modulators of osteogenic protein-1 gene expression |
June 6, 2000 |
| Disclosed are methods and compositions for screening compounds for their ability to modulate expression of a tissue morphogenetic protein, particularly OP-1, OP-1 homologs and closely related proteins, using one or more OP-1-specific, noncoding nucleotide sequences and a suitable rep |
| 6022853 |
Morphogen-enriched dietary composition |
February 8, 2000 |
| Disclosed are methods and compositions useful in dietary applications and capable of enhancing tissue morphogenesis, including tissue development and viability in a mammal, particularly a human. The methods and compositions include a morphogen which, when provided to an individual as |
| 5994131 |
Morphogenic protein screening method |
November 30, 1999 |
| Disclosed is a method of screening candidate compounds for the ability to modulate the level of morphogenic protein in mammalian system. The method includes determining a parameter indicative of the level of production of a morphogenic in a cell culture known to produce the morphogen, in |
| 5972884 |
Morphogen treatment of gastrointestinal ulcers |
October 26, 1999 |
| Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative |
| 5968752 |
Method for identifying an OP-1 analog which binds an ALK-1 receptor |
October 19, 1999 |
| Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features, and various other data characterizing morphogen cell surface receptors, particularly OP-1-binding cell surface receptors, e.g., ALK-1; (2) methods for producing receptor proteins, including f |
| 5932716 |
Morphogen-responsive regulatory elements |
August 3, 1999 |
| Disclosed herein are methods and compositions for identifying morphogen analogs. Preferred methods rest on the use of test cells comprising DNA defining a morphogen-responsive transcription activating element operatively associated with a reporter gene. In certain embodiments, the me |
| 5928940 |
Morphogen-responsive signal transducer and methods of use thereof |
July 27, 1999 |
| A novel gene, DD-10, and its encoded polypeptide chain, DD-10, expressed during early onset of morphogen-induced mammalian tissue morphogenesis, now has been discovered. Accordingly, the invention identifies a new gene which is a novel biological marker of cell differentiation and tissue |
| 5906827 |
Matrix for the manufacture of autogenous replacement body parts |
May 25, 1999 |
| Disclosed are matrices, devices and methods for the manufacture of live autogenous skeletal replacement parts comprising plural different tissues. |
| 5863738 |
Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides |
January 26, 1999 |
| Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features and various other data characterizing a morphogen cell surface receptors particularey OP-1-binding cell surface receptors; (2) methods for producing receptor proteins, including fragments ther |
| 5861479 |
Morphogen cell surface receptor |
January 19, 1999 |
| Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features and various other data characterizing a morphogen cell surface receptor; (2) methods for producing receptor proteins, including fragments thereof, using recombinant DNA technology; (3) methods |
| 5854071 |
OP-3- induced morphongenesis |
December 29, 1998 |
| Disclosed are (1) nucleic acid and amino acid sequences for a novel morphogenic protein; (2) methods for producing and expressing the protein in a biologically active form; and (3) methods for utilizing the protein to induce tissue morphogenesis in a mammal, including methods for inc |
| 5837846 |
Biosynthetic binding proteins for immuno-targeting |
November 17, 1998 |
| Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two |
| 5831050 |
Morphogen cell surface receptor |
November 3, 1998 |
| Disclosed are (1) nucleic acid sequences, amino acid sequences, homologies, structural features and various other data characterizing a morphogen cell surface receptor; (2) methods for producing receptor proteins, including fragments thereof, using recombinant DNA technology; (3) methods |
| 5759815 |
Production of platelet derived growth factor (PDGF) an muteins thereof |
June 2, 1998 |
| Native, analog, and mutein species of A and B chains of platelet derived growth factor are produced in prokaryotes, purified, combined, and modified in vitro to produce various active AA, AB, and BB PDGF dimers. |
| 5753204 |
Biosynthetic binding proteins for immunotargeting |
May 19, 1998 |
| Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two |
| 5741641 |
Morphogenic protein screening method |
April 21, 1998 |
| Disclosed is a method of screening candidate compounds for the ability to modulate the level of morphogenic protein in mammalian system. The method includes determining a parameter indicative of the level of production of a morphogenic in a cell culture known to produce the morphogen, in |
| 5739107 |
Morphogen treatment of gastrointestinal ulcers |
April 14, 1998 |
| Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative |
| 5733878 |
Morphogen-induced periodontal tissue regeneration |
March 31, 1998 |
| Disclosed are methods and compositions for inducing periodontal tissue morphogenesis in a mammal which include a therapeutically effective concentration of a morphogen. The methods and compositions are useful for integrating an implanted tooth in a tooth socket and for inhibiting tissue |
| 5733782 |
Methods and compositions for high protein production from non-native DNA |
March 31, 1998 |
| Disclosed herein are improved methods and compositions for achieving enhanced protein production expressed from non-native gene constructs, including single chain sFv and derivative sequences. The methods and compositions are particularly useful for creating stably transfected, const |
| 5712119 |
Methods and compositions for high protein production form recombinant DNA |
January 27, 1998 |
| Disclosed herein are improved methods and compositions for achieving enhanced protein production expressed from non-native gene constructs, including single chain sFv and derivative sequences. The methods and compositions are particularly useful for creating stably transfected, conti |
| 5707810 |
Method of diagnosing renal tissue damage or disease |
January 13, 1998 |
| In one aspect, the present invention provides a method of diagnosing renal tissue damage or disease by measuring endogenous expression of OP-1 by renal tissue of a mammal (e.g., a human) in which a depression of endogenous expression relative to undamaged or undiseased mammalian renal |
| 5700677 |
Protein analogues of tissue plasminogen activator |
December 23, 1997 |
| Protein analogues of tissue plasminogen activator (tPA) are described. The analogues exhibit the proteolytic function of natural tPA and optionally fibrin binding activity, but are molecules, generally of lower molecular weight than natural tPA, designed for efficient expression in proka |
| 5674844 |
Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
October 7, 1997 |
| The invention is a treatment for increasing the bone mass or preventing bone loss in an individual afflicted with a bone disease which includes administering to the individual a morphogen in a therapeutically effective amount so as to maintain or stimulate bone formation. |
| 5658763 |
Methods and compositions for high protein production from non-native DNA |
August 19, 1997 |
| Disclosed herein are improved methods and compositions for achieving enhanced protein production expressed from non-native gene constructs, including single chain sFv and derivative sequences. The methods and compositions are particularly useful for creating stably transfected, conti |
| 5656593 |
Morphogen induced periodontal tissue regeneration |
August 12, 1997 |
| Disclosed are methods and compositions for inducing periodontal tissue morphogenesis in a mammal which include a therapeutically effective concentration of a morphogen. The methods and compositions are useful for integrating an implanted tooth in a tooth socket and for inhibiting tissue |
| 5652337 |
OP-3-induced morphogenesis |
July 29, 1997 |
| Disclosed are (1) nucleic acid and amino acid sequences for a novel morphogenic protein; (2) methods for producing and expressing the protein in a biologically active form; and (3) methods for utilizing the protein to induce tissue morphogenesis in a mammal, including methods for inc |
| 5652118 |
Nucleic acid encoding a novel morphogenic protein, OP-3 |
July 29, 1997 |
| Disclosed are (1) nucleic acid and amino acid sequences for a novel morphogenic protein; (2) methods for producing and expressing the protein in a biologically active form; and (3) methods for utilizing the protein to induce tissue morphogenesis in a mammal, including methods for inc |
| 5650276 |
Morphogenic protein screening method |
July 22, 1997 |
| Disclosed is a method of screening candidate compounds for the ability to modulate the level of morphogenic protein in mammalian system. The method includes determining a parameter indicative of the level of production of a morphogenic in a cell culture known to produce the morphogen, in |
| 5631159 |
Lipid-modified serum free media |
May 20, 1997 |
| Methods are provided for producing serum-free, animal cell culture media which have enhanced cell culture properties, such as cell growth, cell viability and protein production properties. The cell culture properties of standard serum-free media formulations, which include compositions s |
| 5631158 |
Methods and compositions for high protein production from non-native DNA |
May 20, 1997 |
| Disclosed herein are improved methods and compositions for achieving enhanced protein production expressed from non-native gene constructs, including single chain sFv and derivative sequences. The methods and compositions are particularly useful for creating stably transfected, conti |
| 5614385 |
Methods and compositions for high protein production from recombinant DNA |
March 25, 1997 |
| Disclosed herein are improved methods and compositions for achieving enhanced protein production expressed from non-native gene constructs, including single chain sFv and derivative sequences. The methods and compositions are particularly useful for creating stably transfected, conti |
| 5610021 |
Compositions and methods for identification and use of soluble complex forms of osteogenic prote |
March 11, 1997 |
| Disclosed are novel compositions of osteogenic proteins constituting soluble forms of these proteins, and methods and compositions for distinguishing between soluble and mature forms of these proteins. |
| 5585237 |
Methods and compositions for high protein production from recombinant DNA |
December 17, 1996 |
| Disclosed herein are improved methods and compositions for achieving enhanced protein production expressed from non-native gene constructs, including single chain sFv and derivative sequences. The methods and compositions are particularly useful for creating stably transfected, conti |
| 5534254 |
Biosynthetic binding proteins for immuno-targeting |
July 9, 1996 |
| Disclosed is a formulation for targeting an epitope on an antigen expressed in a mammal. The formulation comprises a pharmaceutically acceptable carrier together with a dimeric biosynthetic construct for binding at least one preselected antigen. The biosynthetic construct contains two |
| 5525491 |
Serine-rich peptide linkers |
June 11, 1996 |
| Disclosed are serine-rich peptide linkers for linking two or more protein domains to form a fused protein. The peptide linkers contains at least 40% serine residues and preferably have the formula (Ser, Ser,Ser,Ser,Gly).sub.y where y is .gtoreq.1. The resulting fused domains are biol |
| 5482858 |
Polypeptide linkers for production of biosynthetic proteins |
January 9, 1996 |
| Disclosed are a family of synthetic proteins having binding affinity for a preselected antigen, and multifunctional proteins having such affinity. The proteins are characterized by one or more sequences of amino acids constituting a region which behaves as a biosynthetic antibody binding |
| 5476786 |
Biosynthetic antibody binding sites |
December 19, 1995 |
| Disclosed are a family of synthetic proteins having affinity for a preselected antigen. The proteins are characterized by one or more sequences of amino acids constituting a region which behaves as a biosynthetic antibody binding site (BABS). The sites comprise 1) non-covalently asso |
| 5418135 |
Method of inhibiting binding of PDGF to a PDGF receptor by biosynthetic PDGF antagonists |
May 23, 1995 |
| Disclosed are polypeptides which antagonize the activity of platelet-derived growth factor (PDGF). These polypeptides include an amino acid sequence sufficiently duplicative of at least a portion of the amino acid sequence of an A chain of PDGF such that the polypeptides bind a cell |
| 5416007 |
Enhanced proteolytic cleavage of recombinant fusion proteins |
May 16, 1995 |
| Disclosed are methods for increasing the yield of intact target proteins by cleaving fused polypeptides made by recombinant DNA techniques. The fused polypeptides are designed at the DNA level to have a preselected primary cleavage site in a pendant polypeptide fused to a protein of inte |
| 5376636 |
Method for promoting tissue repair and regeneration using PDGF and glucocorticoids |
December 27, 1994 |
| Disclosed is a method for the regeneration of tissue, the treatment of external wounds and the treatment of periodontal disease comprising applying to the affected tissue an effective amount of a composition comprised of platelet-derived growth factor (PDGF) and an anti-inflammatory |
| 5374431 |
Synthetic bioadhesive |
December 20, 1994 |
| This invention pertains to a synthetic adhesive composition for use in aqueous environments. The composition comprises polypeptide chains having an .alpha.-helical structure in aqueous environments and capable of cohesive and adhesive interactions. The polypeptide chains comprise polar |
| 5330902 |
Leader sequences for the production of recombinant proteins |
July 19, 1994 |
| Disclosed is a novel polypeptide useful as a leader or trailer peptide moiety in recombinant DNA protein production techniques involving fused protein methodology. The polypeptide comprises an amphiphilic helix designed at the DNA level to have hydrophilic charged amino acid residues |
